Trek Financial LLC Takes $2.83 Million Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Trek Financial LLC purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 58,413 shares of the company's stock, valued at approximately $2,825,000. Trek Financial LLC owned about 0.10% of Protagonist Therapeutics at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership raised its position in Protagonist Therapeutics by 36.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock worth $8,340,000 after buying an additional 58,002 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Protagonist Therapeutics by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock valued at $22,327,000 after purchasing an additional 12,906 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Protagonist Therapeutics by 153.3% during the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock valued at $58,000 after purchasing an additional 728 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Protagonist Therapeutics by 84.1% during the 4th quarter. Victory Capital Management Inc. now owns 240,817 shares of the company's stock valued at $9,296,000 after purchasing an additional 110,020 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in shares of Protagonist Therapeutics by 18.7% during the 4th quarter. Teacher Retirement System of Texas now owns 13,099 shares of the company's stock valued at $506,000 after purchasing an additional 2,067 shares in the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics stock traded up $0.17 during trading on Friday, reaching $53.00. The company had a trading volume of 752,675 shares, compared to its average volume of 843,875. The firm's 50-day simple moving average is $50.03 and its 200 day simple moving average is $45.02. Protagonist Therapeutics, Inc. has a 1-year low of $32.50 and a 1-year high of $60.60. The firm has a market capitalization of $3.28 billion, a PE ratio of 70.67 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.31. Protagonist Therapeutics had a net margin of 27.04% and a return on equity of 9.22%. The company had revenue of $28.32 million for the quarter, compared to analysts' expectations of $30.44 million. Analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on PTGX shares. Citigroup started coverage on shares of Protagonist Therapeutics in a report on Tuesday, June 17th. They set a "buy" rating and a $72.00 target price for the company. Wedbush reaffirmed an "outperform" rating and set a $70.00 target price on shares of Protagonist Therapeutics in a report on Friday, March 28th. Wall Street Zen raised shares of Protagonist Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, June 3rd. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $66.10.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 10,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total transaction of $570,300.00. Following the sale, the insider owned 83,892 shares of the company's stock, valued at $4,784,360.76. The trade was a 10.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Asif Ali sold 1,756 shares of Protagonist Therapeutics stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $46.00, for a total transaction of $80,776.00. Following the sale, the chief financial officer directly owned 61,065 shares in the company, valued at approximately $2,808,990. This trade represents a 2.80% decrease in their position. The disclosure for this sale can be found here. Insiders own 4.90% of the company's stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.